Covered recipient · General Payments record
HARRY EARL STUDDARD
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$1,887.76
105 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,693.36 | 100 |
| Education | $174.40 | 4 |
| Gift | $20.00 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $414.96 | 22 |
| Corcept Therapeutics | $227.32 | 7 |
| Amarin Pharma Inc. | $149.07 | 9 |
| Novo Nordisk Inc | $139.19 | 8 |
| Esperion Therapeutics, Inc. | $98.01 | 7 |
| Vanda Pharmaceuticals Inc. | $97.43 | 4 |
| AstraZeneca Pharmaceuticals LP | $90.66 | 6 |
| Bayer HealthCare Pharmaceuticals Inc. | $72.38 | 5 |
| DEXCOM, INC. | $70.67 | 6 |
| PFIZER INC. | $66.43 | 4 |
| Abbott Laboratories | $62.16 | 3 |
| Lilly USA, LLC | $57.69 | 4 |
| Melinta Therapeutics, LLC | $41.01 | 2 |
| Eisai Inc. | $38.39 | 2 |
| Paratek Pharmaceuticals, Inc. | $37.02 | 2 |
| Xeris Pharmaceuticals, Inc. | $36.83 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $33.60 | 2 |
| Optinose US, Inc. | $28.39 | 2 |
| Nestle HealthCare Nutrition Inc. | $20.22 | 1 |
| KCI USA, Inc. | $19.03 | 1 |
| Antares Pharma, Inc. | $18.72 | 1 |
| Janssen Pharmaceuticals, Inc | $16.08 | 1 |
| Clarus Therapeutics Inc. | $15.12 | 1 |
| Amgen Inc. | $15.04 | 1 |
| Smith+Nephew, Inc. | $11.24 | 1 |
| Kowa Pharmaceuticals America, Inc. | $11.10 | 1 |
Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HARRY EARL STUDDARD
NPI 1144217837 · CMS profile ID 6941
Allopathic & Osteopathic Physicians / Internal Medicine
MOBILE, AL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1144217837?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HARRY EARL STUDDARD, NPI 1144217837, CMS profile ID 6941. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144217837?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). HARRY EARL STUDDARD, NPI 1144217837, CMS profile ID 6941. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144217837?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- HARRY EARL STUDDARD, NPI 1144217837, CMS profile ID 6941, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1144217837?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
105 matching records · $1,887.76 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–105 of 105.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amarin Pharma Inc. | $15.18 | 01/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815386931 | CMS |
| Eisai Inc. | $19.32 | 01/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 817808353 | CMS |
| Antares Pharma, Inc. | $18.72 | 01/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827485085 | CMS |
| AbbVie Inc. | $16.57 | 01/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796106561 | CMS |
| Esperion Therapeutics, Inc. | $13.55 | 01/04/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838416051 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,466,022.53 | 240 |
| PY2024 | Recipient | $26,171.00 | 2 |
| PY2024 | Principal investigator | $2,306,086.10 | 175 |
| PY2023 | Recipient | $620.01 | 1 |
| PY2023 | Principal investigator | $1,267,298.09 | 431 |
| PY2022 | Principal investigator | $2,872,636.12 | 235 |
| PY2021 | Principal investigator | $1,852,676.67 | 133 |
| PY2020 | Principal investigator | $1,424,628.27 | 352 |
| PY2019 | Principal investigator | $1,686,079.54 | 965 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
240 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca UK Limited | $2,180.00 | 12/31/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight or Obesity | No dispute reported | 06/30/2026 | 1185555437 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $897.50 | 12/24/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715516 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228722756 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725248 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725530 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725700 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228730855 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228730858 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228732839 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228733394 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228733401 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228733647 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228733651 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228733901 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228733906 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228734020 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228734811 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228734815 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228734820 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735031 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735161 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/22/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228737003 |
| Principal investigator 1 | PFIZER INC. | $1,170.00 | 12/18/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228729147 |
| Principal investigator 1 | PFIZER INC. | $1,170.00 | 12/18/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228729152 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 12/17/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725584 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.92 | 12/17/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725586 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,777.32 | 12/15/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 12/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725562 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725564 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 12/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725566 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725568 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725570 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725572 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725574 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725576 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $7,375.20 | 11/21/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107427 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 11/19/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725578 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 11/19/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725580 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 11/19/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725582 |
| Principal investigator 1 | ViiV Healthcare Company | $1,000.00 | 11/19/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI | No dispute reported | 06/30/2026 | 1190317715 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $16,588.00 | 11/12/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure | No dispute reported | 06/30/2026 | 1185555439 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,524.88 | 11/12/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214738 |
| Principal investigator 1 | ViiV Healthcare Company | $38,803.99 | 11/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI | No dispute reported | 06/30/2026 | 1190317719 |
| Principal investigator 1 | Janssen Research & Development, LLC | $287.00 | 11/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARC | A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older | No dispute reported | 06/30/2026 | 1175400696 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $650.00 | 11/03/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107333 |
| Principal investigator 1 | ViiV Healthcare Company | $12,318.27 | 11/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI | No dispute reported | 06/30/2026 | 1190314995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725550 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725552 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725554 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725556 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725558 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725560 |
| Principal investigator 1 | PFIZER INC. | $8,446.00 | 11/01/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228739327 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $436.80 | 10/30/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107643 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $650.00 | 10/30/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107648 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,906.00 | 10/30/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107654 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,500.00 | 10/30/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107662 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,600.00 | 10/30/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107668 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,926.00 | 10/29/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214752 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,130.30 | 10/29/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798597 |
| Principal investigator 1 | ViiV Healthcare Company | $13,500.00 | 10/29/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI | No dispute reported | 06/30/2026 | 1190317717 |
| Principal investigator 1 | Eli Lilly and Company | $22,794.96 | 10/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187877843 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,200.00 | 10/23/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715504 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $22,125.60 | 10/23/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107546 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $105.00 | 10/22/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798591 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $279.00 | 10/22/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798593 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $315.00 | 10/22/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798595 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $450.00 | 10/22/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798885 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $465.00 | 10/22/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798887 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $14,567.00 | 10/17/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107377 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 10/16/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARC | A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older | No dispute reported | 06/30/2026 | 1175400710 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,733.00 | 10/16/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARC | A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older | No dispute reported | 06/30/2026 | 1175400731 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 10/16/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARC | A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older | No dispute reported | 06/30/2026 | 1175400741 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $145.38 | 10/15/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185555433 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,542.25 | 10/14/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715492 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,142.40 | 10/14/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715496 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,498.00 | 10/14/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715498 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,142.40 | 10/14/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715500 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,142.40 | 10/14/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715502 |
| Principal investigator 1 | PFIZER INC. | $1,715.28 | 10/08/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228714164 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $450.00 | 10/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798583 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $105.00 | 10/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798585 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500.00 | 10/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798587 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,350.00 | 10/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798589 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $795.00 | 10/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798875 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $450.00 | 10/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798877 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $105.00 | 10/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798879 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $450.00 | 10/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798881 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $594.00 | 10/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798883 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,000.00 | 10/03/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798599 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725538 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725540 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725542 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725544 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725546 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725548 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,520.37 | 09/26/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 09/24/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725530 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $511.00 | 09/24/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725532 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.00 | 09/24/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725534 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17.40 | 09/24/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725536 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/22/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808018 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,910.96 | 09/18/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798581 |
| Principal investigator 1 | PFIZER INC. | $571.76 | 09/03/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228743293 |
| Principal investigator 1 | PFIZER INC. | $5,866.42 | 09/03/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228750965 |
| Principal investigator 1 | ViiV Healthcare Company | $14,094.88 | 09/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH MOBILE | A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI | No dispute reported | 06/30/2026 | 1190317721 |
| Principal investigator 1 | Bavarian Nordic A/S | $19,335.94 | 09/02/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214708 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725496 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725498 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725500 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725502 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725504 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725522 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 09/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725524 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,058.50 | 08/26/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725526 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.66 | 08/26/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725528 |
| Principal investigator 1 | ViiV Healthcare Company | $25,211.88 | 08/22/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH MOBILE | A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI | No dispute reported | 06/30/2026 | 1190317723 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,986.06 | 08/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798579 |
| Principal investigator 1 | PFIZER INC. | $5,225.64 | 08/05/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228768161 |
| Principal investigator 1 | Bavarian Nordic A/S | $371.80 | 08/01/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214698 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725478 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725480 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725482 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725484 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725486 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725488 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725490 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725492 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725494 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 08/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725516 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725520 |
| Principal investigator 1 | PFIZER INC. | $3,791.20 | 07/17/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228785486 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725506 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725508 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725510 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725512 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725514 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725518 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,218.90 | 06/26/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798577 |
| Principal investigator 1 | PFIZER INC. | $7,369.60 | 06/26/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228793554 |
| Principal investigator 1 | Bavarian Nordic A/S | $743.60 | 06/25/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214664 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 06/24/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725472 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 06/24/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725474 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 06/24/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725476 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $2,677.70 | 06/24/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715482 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,801.00 | 06/13/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226113116 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,735.64 | 06/11/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A PHASE I/II OBSERVER-BLIND, RANDOMIZED, MULTI-CENTER TRIAL TO EVALUAT | No dispute reported | 06/30/2026 | 1192109603 |
| Principal investigator 1 | Bavarian Nordic A/S | $5,261.63 | 06/04/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214656 |
| Principal investigator 1 | Bavarian Nordic A/S | $680.34 | 06/02/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214692 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725452 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725454 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725456 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725458 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725460 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725462 |
| Principal investigator 1 | PFIZER INC. | $15,852.20 | 05/29/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228772902 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $2,326.95 | 05/28/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715474 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 05/27/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725468 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 05/27/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725470 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $34,971.16 | 05/16/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226113784 |
| Principal investigator 1 | ViiV Healthcare Company | $80,282.72 | 05/15/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A PHASE 1 SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINETI | No dispute reported | 06/30/2026 | 1190317725 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,049.58 | 05/09/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798575 |
| Principal investigator 1 | PFIZER INC. | $14,100.00 | 05/06/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228773790 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725438 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $64.50 | 05/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725440 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725442 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725444 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725446 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725448 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725450 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $199,767.64 | 04/28/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226113518 |
| Principal investigator 1 | Bavarian Nordic A/S | $15,452.23 | 04/25/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214654 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $3,771.20 | 04/24/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715466 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 04/23/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725464 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 04/23/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725466 |
| Principal investigator 1 | PFIZER INC. | $3,448.16 | 04/15/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707552 |
| Principal investigator 1 | PFIZER INC. | $3,448.16 | 04/15/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228759866 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,778.48 | 04/11/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798573 |
| Principal investigator 1 | PFIZER INC. | $7,327.34 | 04/08/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707554 |
| Principal investigator 1 | PFIZER INC. | $7,327.34 | 04/08/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228761088 |
| Principal investigator 1 | PFIZER INC. | $15,839.67 | 04/08/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228781391 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725426 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725428 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725430 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725432 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725434 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725436 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $5,340.60 | 03/27/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715442 |
| Principal investigator 1 | Bavarian Nordic A/S | $9,439.20 | 03/26/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214612 |
| Principal investigator 1 | Bavarian Nordic A/S | $50,409.27 | 03/21/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214608 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,972.44 | 03/17/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798571 |
| Principal investigator 1 | PFIZER INC. | $1,279.80 | 03/17/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC Mobile | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228713990 |
| Principal investigator 1 | PFIZER INC. | $677.05 | 03/17/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228774149 |
| Principal investigator 1 | PFIZER INC. | $793.65 | 03/17/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228774153 |
| Principal investigator 1 | PFIZER INC. | $793.65 | 03/17/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228775916 |
| Principal investigator 1 | PFIZER INC. | $677.05 | 03/17/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research | A PHASE 3 MULTICENTER PARALLELGROUP OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS 50 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228786397 |
| Principal investigator 1 | Bavarian Nordic A/S | $49,018.75 | 03/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214596 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725406 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725408 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725410 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725412 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725414 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725416 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,142.40 | 02/27/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715410 |
| Principal investigator 1 | Amgen Inc. | $49,367.45 | 02/25/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246639027 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 02/25/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725418 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 02/25/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725420 |
| Principal investigator 1 | Eli Lilly and Company | $4,164.97 | 02/25/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187874491 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $4,329.95 | 02/20/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715428 |
| Principal investigator 1 | PFIZER INC. | $50,805.60 | 02/08/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228757604 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $571.20 | 02/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715406 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $856.80 | 02/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715408 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725394 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725396 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725398 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725400 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725402 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725404 |
| Principal investigator 1 | Eli Lilly and Company | $150.00 | 01/31/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | No dispute reported | 06/30/2026 | 1187880539 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,100.00 | 01/30/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715414 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,444.25 | 01/30/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715422 |
| Principal investigator 1 | Eli Lilly and Company | $28,660.00 | 01/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187872545 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,296.28 | 01/27/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798569 |
| Principal investigator 1 | Amgen Inc. | $277,598.08 | 01/26/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | No dispute reported | 06/30/2026 | 1246639043 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228799104 |
| Principal investigator 1 | Eli Lilly and Company | $92,479.00 | 01/21/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLS | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187876279 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,679.32 | 01/17/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798567 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,311.00 | 01/15/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214632 |
| Principal investigator 1 | Bavarian Nordic A/S | $262.20 | 01/15/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214634 |
| Principal investigator 1 | Bavarian Nordic A/S | $262.20 | 01/15/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214758 |
| Principal investigator 1 | PFIZER INC. | $2,088.52 | 01/15/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228719969 |
| Principal investigator 1 | PFIZER INC. | $5,000.00 | 01/15/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228801494 |
| Principal investigator 1 | AstraZeneca UK Limited | $47,361.90 | 01/13/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185555435 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725384 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725386 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725388 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725390 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725392 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 01/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725422 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Amr Coastal Clinical Research-Mobile | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220725424 |